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Hepatitis B virus (HBV) is unusual in that its surface proteins (S, M and L for 
small, medium and large) are not only incorporated into the virion envelope, 
but they also bud into empty subviral particles, in great excess over virions. 
The morphogenesis of these subviral envelope particles remains unclear, but 
the S protein is essential and sufficient for budding. We show here that in 
contrast to the presumed model, the HBV subviral particle formed by the S 
protein self-assembles into branched filaments in the lumen of the 
endoplasmic reticulum (ER). These long filaments are then folded and bridged 
for packing into crystal-like structures, which are then transported by ER-
derived vesicles to the ER-Golgi intermediate compartment (ERGIC). Within the 
ERGIC, they are unpacked and relaxed, and their size and shape probably 
limits further progression through the secretory pathway. Such progression 
requires their conversion into spherical particles, which occurred 
spontaneously during the purification of these filaments by affinity 
chromatography. Small branched filaments are also formed by the L protein in 
the ER lumen, but these filaments are not packed into transport vesicles. They 
are transported less efficiently to the ERGIC, potentially accounting for the 
retention of the L protein within cells. These findings shed light on an 
important step in the HBV infectious cycle, as the intracellular accumulation of 




The human hepatitis B virus (HBV) is the prototype of the mammalian 
Hepadnaviridae (genus Orthohepadnavirus), a family of small hepatotropic DNA 
viruses causing acute and chronic liver disease (16). Despite the existence of an 
effective hepatitis B vaccine, HBV remains a major health problem worldwide, as 
there is no generally effective treatment for the estimated 350 million chronic carriers 
who have a high risk of liver cirrhosis and hepatocellular carcinoma. A thorough 
understanding of HBV morphogenesis and life cycle is thus required for the 
development of innovative antiviral treatments. The virion (or Dane particle) is a 
spherical particle, 42 nm in diameter, consisting of an icosahedral nucleocapsid of 
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approximately 30 nm in diameter and an envelope composed of three surface 
proteins and, presumably, lipids of host cell origin. The nucleocapsid and envelope 
are synthesized and mature separately in different cellular compartments, 
subsequently interacting to form the virion (5, 26, 34). The three HBV envelope 
proteins are encoded by a single open reading frame (ORF), using three in-frame 
start codons (21). The large surface protein (L, or p39) is the translation product of 
the entire ORF (389 to 400 amino acid residues [aa], depending on HBV genotype). 
The middle surface protein (M, or p30) lacks the N-terminal 119 aa of L (the pre-S1 
sequence), and the small surface protein (S, or p24) lacks the N-terminal 55 aa of M 
(the pre-S2 sequence). These proteins are synthesized at the endoplasmic reticulum 
(ER) membrane and have a complex transmembrane topology (12, 13). They form 
disulfide-linked dimers with each other, with no detectable partner preference (27, 
45). All three proteins have a form glycosylated at residue N146 in the S domain 
(gp27, gp33 and gp42 for S, M and L, respectively), but about half the molecules 
produced remain unglycosylated at this site. The M protein may also be glycosylated 
(ggp36) at N4 in the pre-S2 domain (17). 
HBV and related viruses are unusual among viruses in that the surface 
proteins are not only incorporated into virion envelopes, they also bud to generate 
empty subviral spherical or filamentous particles without nucleocapsids in an 
intracellular compartment, these particles being formed in great excess over virions 
(21). The S protein is the predominant constituent of these subviral particles and is 
the essential topogenic element for this budding, with no other viral protein required. 
Indeed, the production of S protein alone in mammalian cells causes efficient 
secretion of 20 nm-large subviral particles, also called HBs Ag particles (11, 29). This 
material is highly immunogenic and is the basis of most vaccines against hepatitis B 
(14). The type of particle formed seems to be determined by the ratio of S to L 
proteins coassembling during morphogenesis. The spherical 20 nm HBs Ag particles 
isolated from the serum of infected patients contain only traces of L protein (21). The 
coassembly of a higher proportion of L protein with S results in formation of the 
filamentous form of HBs Ag (21). This high L content inhibits particle secretion (32), 
due to specific retention motifs in this protein (15, 35) and/or the inefficient export of 
the filamentous particles (39). The L protein plays a key role in virus assembly and 
infectivity, and is therefore present in large proportions in the virion envelope (6, 8, 
21). The M protein seems to have no determining influence on particle morphology, 
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because this protein is present in all three particles, in proportions similar to that for S 
(21). This protein is also dispensable for virion formation in vitro (6). It is widely 
accepted that subviral particles self-assemble at a post-ER/pre-Golgi compartment 
(ERGIC for ER-Golgi intermediate compartment), together with lipids (24), before 
their secretion in the constitutive secretory pathway. However, little is known about 
the molecular mechanisms of the transition of the HBs Ag from the transmembrane 
to the particulate state, and the intracellular trafficking of this particle.  
We have recently shed new light on hepatitis C virus (HCV) morphogenesis, 
by developing a model based on the production of HCV structural proteins from 
Semliki Forest Virus (SFV)-derived vectors (1, 2). This model made it possible for the 
first time to visualize, by electron microscopy (EM), viral assembly and budding at the 
ER membrane (38). We therefore adopted a similar approach for studies of HBV 
subviral envelope particle morphogenesis.  
 
MATERIALS AND METHODS 
 
 Plasmid construction. The original plasmid pHBV1.5 (generously provided 
by Dr Volker Bruss), containing an overlength copy of the HBV DNA subtype adw (6), 
was used to extract the sequences encoding the three HBV envelope proteins. We 
constructed pSFV1-SHBsadw by amplifying a DNA fragment encoding the S protein 
by PCR from pHBV1.5, using a proofreading Taq DNA polymerase (PfuTurbo DNA 
polymerase, Stratagene) and primers flanked by BamHI restriction endonuclease site 
sequences (underlined): 5’-Sadw (5’ – 
ATAGGATCCATGGAGAACATCACATCAGGATTCC – 3’) and 3’-Sadw (5’ – 
ATAGGATCCTTATTAAATGTATACCCAGAGACAAAAGAAAAT – 3’). The start 
codon and inserted stop codon are indicated in bold typeface. The PCR product was 
inserted into pGEM-T (pGEM-T Easy Vector System, Promega) and then into the 
BamHI restriction site of the pSFV1 vector (Invitrogen). The plasmids pSFV1-
MHBsadw and pSFV1-LHBsadw were obtained in a similar manner, using specific 
primers flanked by XmaI restriction endonuclease site sequences (underlined): 5’-
Madw (5’ – ATACCCGGGATGCAGTGGAATTCCA – 3’) and 5’-Ladw (5’ – 
ATACCCGGGATGGGAGGTTGGTCAT – 3’) for the M and L sequences 
respectively, and 3’-MLadw (5’ – 
ATACCCGGGTTATTAAATGTATACCCAGAGACAA – 3’) for both M and L 
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sequences. All PCR products (702 bp, 867 bp and 1224 bp for S, M and L, 
respectively) were verified by DNA sequencing. 
 Cell Culture and RNA Transfection. Baby Hamster Kidney cells (BHK-21) 
were maintained in Glasgow Minimal Essential Medium (Invitrogen) supplemented 
with 5 % fetal bovine serum (ATGC), 8 % tryptose phosphate (Sigma), 100 IU/mL 
penicillin and 100 µg/mL streptomycin, in a standard cell incubator, at 37°C under an 
atmosphere containing 5 % CO2. For recombinant RNA synthesis, pSFV1 constructs, 
which contain an SP6 RNA polymerase promoter upstream from the 5’ SFV UTR, 
were linearized at the single SpeI site downstream from the multiple cloning site. 
Linear DNA was transcribed in vitro, using SP6 RNA polymerase, according to the 
standard protocol provided by the manufacturer (Promega). For the negative control, 
recombinant RNA encoding -Galactosidase (-Gal) was synthesized from the 
pSFV3 expression vector (Invitrogen). BHK-21 cells (106) were trypsinized, washed 
in phosphate-buffered saline (PBS) and mixed with 10 µg of the various recombinant 
SFV RNAs. They were then electroporated, using a single exponential decay pulse at 
350 V, 750 µF in a Gene Pulser Xcell (Biorad). Immediately after electroporation, 
cells were diluted in growth medium, plated in a 75 cm2 culture dish (Falcon) and 
cultured for 16 hours (unless otherwise specified) before analysis. For confocal 
microscopy, electroporated cells were cultured directly on 12 mm coverslip in a 24-
well plate, at a density of 105 cells per coverslip. 
 Western Blotting. Sixteen hours after transfection, cells were lysed with 1 % 
NP-40 in Tris-EDTA buffer (1 M Tris pH 8, 1 mM EDTA) supplemented with protein 
inhibitor cocktail (1 mM phenylmethylsulfonyl, 2 µg/mL aprotinin, 2 µg/mL leupeptin). 
The lysates were clarified by centrifugation at 4°C for 20 minutes at 12000g. An 
aliquot of the supernatants was processed for the assessment of protein 
concentration by the Lowry method. The supernatants were boiled for 5 minutes in 
disruption buffer (Laemmli buffer containing 5 % -mercaptoethanol). For western 
blotting, 10 g of total proteins were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) in a 12 % acrylamide gel and 
transferred to a polyvinylidene difluoride (PVDF) membrane (Hybond P, Amersham). 
Unsatured sites on the PVDF membranes were blocked with 2 % (wt/vol) non fat milk 
powder in Tris-buffered saline (TBS) for one hour at room temperature. The 
membranes were then incubated overnight at 4°C with the rabbit polyclonal antibody 
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(PAb) anti-HBsAg (R247) (25), diluted 1:2000 in blocking buffer. This antiserum is 
specific for a linear epitope located between residues 54 and 64 of the S domain (D 
genotype, aym3 subtype). Membranes were washed with 0.3 % (v/v) Tween in TBS 
(TBS-T), and incubated for one hour at room temperature with horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit antibody (Biosource), diluted 1:5000 in 
blocking buffer. Immunoblots were developed by enhanced chemiluminescence (ECL 
kit, Amersham) and placed against Kodak Biomax Light films for the detection of light 
emission. 
 Confocal Microscopy. Sixteen hours after transfection, cells grown on 
coverslips were washed in PBS and fixed by incubation with 4 % paraformaldehyde 
in PBS for 30 minutes at room temperature. Free aldehyde groups were blocked by 
incubation with 100 mM glycine in PBS for 10 minutes. The cells were then 
permeabilized by incubation for 30 minutes with 0.05 % saponin, 0.2 % bovine serum 
albumin (BSA) in PBS. They were then incubated for 30 minutes at room 
temperature in a dark, humid chamber, with mouse monoclonal antibody (MAb) anti-
HBsAg (H25B10, ATCC), rabbit polyclonal antibody (Pab) against calreticulin (anti-
CRT, Stressgen) or rabbit PAb against ERGIC53 (Axxora) diluted 1:100, 1:200 and 
1:500, respectively, in permeabilization buffer. Cells were washed three times in PBS 
and incubated with Alexa 488-conjugated goat anti-mouse and Alexa 594-conjugated 
goat anti-rabbit secondary antibodies (Molecular Probes), diluted 1:2000 and 1:5000, 
respectively, in permeabilization buffer. Cells were washed three times in PBS and 
were then mounted in 25 mM Tris pH 8.8, 5 % glycerol, 2.5 % 1,4-
diazabicyclo[2,2,2]octane (DABCO) and 10 % polyvinylalcohol MW range 31000-
50000 (Sigma). The mounted cells were examined with an Olympus Fluoview 500 
confocal laser scanning microscope (Olympus). 
 Ultrastructural analysis of the transfected cells by EM. Cells were fixed 
directly in the culture dish 16 hours after electroporation, by incubation for 48 hours in 
4 % paraformaldehyde and 1 % glutaraldehyde in 0.1 M phosphate buffer pH 7.2. In 
some experiments, cells transfected with the pSFV1-SHBsadw construct were 
subjected to kinetic analysis with fixation 4, 8 and 12 hours after electroporation. 
Cells were scraped off with a Cell Scraper (Falcon), washed in PBS, post-fixed for 1 
hour with 1 % osmium tetroxide and dehydrated in a graded series of ethanol 
solutions. Cell pellets were embedded in Epon resin (Sigma), which was allowed to 
polymerize for 48 hours at 60°C. Ultrathin sections were cut, stained with 5 % uranyl 
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acetate and 5 % lead citrate, and deposited on EM grids coated with collodion 
membrane, for examination under a Jeol 1010 transmission electron microscope 
(TEM). For immuno-EM, transfected BHK-21 cells were fixed by incubation in 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.2) for 3 h. The cell pellet was then 
dehydrated in a graded series of ethanol solutions at –20°C, using an automatic 
freezing substitution system (AFS, Leica), and embedded in London Resin white 
(Electron Microscopy Science). The resin was allowed to polymerize at –25°C, under 
UV light, for 72 h. Ultrathin sections were blocked by incubation with 1% fraction V 
bovine serum albumin (BSA, Sigma) in PBS and incubated with the rabbit PAb 
against HBs Ag, diluted 1:50 in PBS. Immunolabeling was detected by incubation 
with gold-conjugated goat anti-rabbit IgG antibodies (British Biocell International) 
diluted 1:100 in PBS. Ultrathin sections were cut and stained as above and observed 
with a Jeol 1010 TEM. 
HBV subviral envelope particle purification and negative staining by EM. 
Sixteen hours after transfection, cells were collected from 20 75 cm2 culture dishes, 
treated with trypsin, pooled and resuspended in Tris-NaCl buffer (10 mM Tris pH 8, 
140 mM NaCl) supplemented with protein inhibitor cocktail (1 mM 
phenylmethylsulfonyl fluoride, 2 µg/mL aprotinin, 2 µg/mL leupeptin). Cells were 
lysed by heat shock (2 minutes in liquid nitrogen followed immediately by 2 minutes 
at 37°C, repeated) and homogenized for 10 minutes on ice. The samples were 
centrifuged at 4°C, for 15 minutes, at 15000 rpm in an SW41 rotor (Beckman) and 
the supernatants were concentrated with an Amicon Ultracell-100k device 
(Millipore). They were then layered onto the top of a discontinuous sucrose gradient 
(25 to 60 % in 20 mM Tris pH 8), and centrifuged at 4°C for 16 hours at 28000 rpm in 
an SW 41 rotor (Beckman). The collected fractions were quantified by 
immunocapture ELISA, using Maxisorp plates (Nunc) coated with the mouse anti-
HBs MAb H25B10 (ATCC), using the biotinylated mouse anti-HBs MAb H25B10 as a 
detection reagent. Positive fractions were pooled and dialyzed, using a Slide-A-
Lyser 10000 MWCO dialysis cassette (Pierce Perbio), against 20 mM Tris pH 8 at 
4°C, and then concentrated using an Amicon Ultracell-100k (Millipore) device. This 
crude preparation (10 l) was then deposited on EM carbon-coated grids, negatively 
stained with 1 % uranyl acetate, and analyzed under the TEM. For immunogold 
labeling, 10 l of the preparation was first incubated overnight at 4°C with the rabbit 
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anti-HBs PAb R247, diluted 1:100 in PBS. It was then incubated for 3 hours at room 
temperature with gold-conjugated goat anti-rabbit IgG antibodies (British Biocell 
International) diluted 1:50 in PBS. Negative staining was then carried out as 
described above.  
HBV subviral envelope particles were further purified from the initial crude 
preparation by anti-HBs affinity chromatography. Briefly, the anti-HBs MAb H25B10 
was coupled through carbohydrates present in its Fc region, to resin, by mild 
reduction of the carbohydrate moiety with sodium meta-periodate, followed by 
covalent coupling to hydrazide gel (CarboLink coupling gel, Pierce). For 
chromatography, the column was equilibrated with PBS and concentrated samples 
were loaded onto the column at a flow rate of 1 mL/minute with monitoring of 
absorbance at 280 nm. Once the samples were loaded, the column was washed with 
PBS until absorbance reached baseline values. Immunoadsorbed HBsAg particles 
were eluted with 0.1 M citrate pH 2.9, then collected in 1 mL fractions in tubes 
containing 0.115 mL of 1 M Tris base, for rapid neutralization of the eluted material. 
The collected fractions were quantified with the immunocapture ELISA described 
above. Positive fractions were pooled and dialyzed, using a Slide-A-Lyser 10000 
MWCO dialysis cassette (Pierce Perbio), against 20 mM Tris pH 8 at 4°C. They were 
then concentrated, using an Amicon Ultracell-100k (Millipore) device. This final 
preparation was negatively stained and examined under the TEM as described 
above. 
HBs Ag quantification in the cell supernatants. The amount of HBs Ag 
present in the supernatant of cells transfected with the various constructs was 
quantified with the ELISA described above, using sequential dilutions of a 




Ultrastructural changes induced by the production of the HBV S 
envelope protein. Sixteen hours after transfection with the SFV recombinant 
construct expressing the DNA sequence encoding the HBV S protein, BHK-21 cells 
were harvested and lysed for western blot analysis (Fig. 1, lane 2). Consistent with 
previous studies, the S protein was detected in similar quantities of the 
unglycosylated (p24) and glycosylated (gp27) forms. Confocal microscopy on cells 
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grown on glass coverslips showed that the S protein colocalized with calreticulin, a 
specific ER marker, and with the ERGIC marker ERGIC53, mostly in the perinuclear 
area (Fig. 2, SHBs). Cells transfected with -Gal RNA gave no signal with anti-HBs 
antibodies on western blots or on confocal microscopy (Fig. 1 lane 1 and Fig. 2).  
Cells producing the S protein displayed significant ultrastructural modifications 
on EM (Figs. 3 and 4) with respect to the cells producing -Gal (not shown on 
figures). Intracellular vesicles, packed with filaments, were abundantly observed in 
the perinuclear area of these cells (Fig. 3). These vesicles clearly originated from the 
ER, as they were frequently observed budding from the nuclear envelope (Fig. 3A) or 
from membranes with ribosomes at their surface (Fig. 3B). They were homogeneous 
in size (between 0.2 and 0.3 micrometers in diameter) and were filled with packed 
and presumably bridged filaments, 22-nm in diameter, which were observed in 
lengthwise or crosswise sections in crystalline structures (Fig. 3C and 3D). The 
specificity of the content of these vesicles was determined by immunogold labeling 
with the rabbit PAb against HBs Ag. Modifications to the fixation and embedding 
procedures required for this specific immunostaining method (particularly the 
absence of glutaraldehyde and osmium tetroxide), resulted in the cell structures and 
filaments being less well preserved than in cells embedded in Epon resin according 
to standard EM methods. However, intense gold labeling restricted to these vesicles 
was observed in the perinuclear area (inset in Fig. 3D). We carried out a time course 
analysis and found that these vesicles became detectable as early as 12 hours after 
transfection, and that their frequency peaked 16 hours after transfection.  
We also observed very large cisternae (1 to 2 micrometers in diameter) in 
some cells. These cisternae were delimited by smooth membranes and contained 
relaxed long filaments (Fig. 4). Their lumina presumably contained material from the 
smaller vesicles described above. Indeed, fusion with the cisternae of vesicles 
containing 22 nm packed filaments was frequently observed (large arrows in Figs. 
4B, 4C and 4D). The 22 nm filaments in the lumina of the cisternae were mostly fully 
relaxed, but in some cases, the filaments were relaxed at one end but remained 
bridged in a crystalline structure with other filaments at the other (small arrows in 
Figs. 4A, 4C and 4D). When relaxed, the end of the filament was electron-dense (see 
the inset in Fig. 4A). These cisternae were observed in cells fixed 16 hours after 
transfection, but not in cells fixed 4, 8 or 12 hours after transfection.  
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Negative staining of the intracellular subviral particles formed by the 
HBV S envelope protein. Initial analysis of the crude cell lysate subjected to 
centrifugation on a sucrose gradient led to the observation of long filaments 22 nm in 
diameter (Figs. 5A and 5B). These filaments were well organized, with negative 
staining revealing a regular crenellated appearance (Fig. 5A and 5B). They were of 
various sizes, and were often branched (arrows in Fig. 5B). The longest unbranched 
filament found in this preparation was 1.2 micrometers in length (not shown on the 
figure). The filaments had bulging extremities, probably accounting for the electron-
dense appearance of these extremities in ultrathin sections (see our comment 
concerning the inset in Fig. 4A above). The specificity of these filaments was 
confirmed by immunogold labeling. Following prior incubation with the rabbit anti-HBs 
PAb, the filaments were immunoagglutined and labeled with gold-conjugated goat 
anti-rabbit IgG antibodies (inset in Fig. 5A). Following purification by affinity 
chromatography, these filaments were systematically unbranched and much smaller 
(less than 0.3 micrometers in length), and their ends showed a clear tendency to 
dissociation into subviral spherical particles (Figs. 5C and 5D). 
Ultrastructural changes induced by the production of the HBV M or L 
envelope proteins. Sixteen hours after transfection with the recombinant SFV 
constructs containing the DNA sequence of the HBV M or L proteins, BHK-21 cells 
were harvested and lysed for western blot analysis (Fig. 1). Expression of the 
pSFV1-MHBsadw construct gave large amounts of glycosylated M protein in cells, with 
equal amounts of the two main forms (ggp36 and gp33), but only traces of the 
unglycosylated form (p30). This construct also yielded small amounts of the two 
forms of the HBV S envelope protein, p24 and gp27 (Fig. 1, lane 3). Expression of 
the pSFV1-LHBsadw construct yielded large amounts of L protein, with similar 
amounts of the unglycosylated (p39) and glycosylated (gp42) forms. In contrast to 
what was observed for pSFV1-MHBsadw, the expression of pSFV1-LHBsadw resulted 
in the production of only tiny amounts of S proteins. However, expression of this 
construct yielded two glycosylated forms of M (Fig. 1, lane 4). ELISA showed that 
HBsAg levels were higher in the supernatant of cells transfected with the pSFV1-
MHBsadw construct than in that of cells transfected with the pSFV1-SHBsadw construct 
(4.6 ng/mL and 1.8 ng/mL, respectively), whereas no HBs Ag was detected in the 
supernatant of cells transfected with the pSFV1-LHBsadw and -Gal constructs (Fig. 
1). Immunocytochemistry and confocal microscopy showed that the HBV M protein 
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was partly colocalized with calreticulin and ERGIC53 (Fig. 2), and that the subcellular 
distribution of this protein was more diffuse than that of the HBV S protein (Fig. 2). 
The HBV L protein colocalized mostly with calreticulin and, to a lower extend, with 
ERGIC53, in the perinuclear area of the cells (Fig. 2).  
Despite an intensive search and repeated experiments, no ultrastructural 
changes were detected in cells transfected with the pSFV1-MHBsadw construct (Fig. 
6A). In particular, no filamentous or spherical subviral particles were observed in 
these cells. In contrast, cells transfected with the pSFV1-LHBsadw construct showed 
dilated convoluted compartments containing filamentous particles (Figs. 6B and 6C). 
This compartment was probably ER-related, as its membranes were rough and 
sometimes continuous with the external membrane of the nuclear envelope (Fig. 6B). 
However, it was much more heterogeneous in size and shape than the ER-related 
vesicles found in cells producing the HBV S envelope protein. The filaments formed 
by the HBV L protein also clearly differed from those formed by the HBV S protein: 
they were slightly larger in diameter, highly branched, unpacked and unbridged (Figs. 
6B and 6C). Despite an intensive search, no large cisternae such as those found in 
cells transfected with the pSFV1-SHBsadw construct were detected in these cells. 
Negative staining of intracellular subviral particles formed by the HBV L 
envelope protein. Analysis of the crude cell lysate subjected to centrifugation on a 
sucrose gradient revealed the presence of some small, branched filaments with a 
diameter of 30 nm (Fig. 6D). This observation confirmed that the filaments formed by 
the HBV L protein differed from those formed by the HBV S protein. They were larger 
in diameter (30 nm) but much smaller in length (less than 0.5 micrometers). Attempts 
to purify these filaments further by affinity chromatography were unsuccessful, 
probably due to their low rate of recovery from the cell lysate and/or their weak 
binding to the anti-HBs antibody with which the column was coated. We also 
analyzed a lysate from cells producing the M protein, and confirmed the absence of 
any filamentous or spherical subviral particles in these cells, at least in sufficient 




Despite the existence of hepatoma cell lines that can produce infectious virus 
after transfection with the viral genome (40, 43) and the recent establishment of a cell 
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line that can be infected by the virus in vitro (20), little is known about the 
morphogenesis of HBV. This may be due to the low rate of HBV production in these 
cells, as it has been estimated that an individual hepatocyte releases only 1 to 10 
viruses per day during the productive phase of infection in vivo (30). HBV subviral 
envelope particles can reach concentrations 10,000 times higher than that of virions 
in the serum of infected patients, but their assembly and intracellular transport also 
remain poorly understood (4). 
As the production of the S envelope protein alone is sufficient for the secretion 
of spherical HBV subviral envelope particles, it is widely thought that the filamentous 
shape of these particles results from the coproduction of the S and L proteins (7, 21). 
Our EM study showed that the production of the HBV S protein alone also led, at 
least initially, to the morphogenesis of filamentous subviral particles. The existence of 
this phenomenon was suggested in early EM studies on Chinese hamster ovary 
(CHO) cells producing the HBV S protein (31), but it has not been studied further in 
the last 20 years. The filaments induced by the HBV S protein in our study seemed to 
be extremely long (up to 1.2 micrometers) and occasionally branched, a feature that 
was also considered specific to filaments induced by HBV L protein overproduction in 
a transgenic mouse model (9). 
Our study shows that the morphogenesis of these filaments takes place in the 
ER. The currently accepted model of the subviral HBV particle formation assumes 
that this process takes place at the ERGIC membrane, resulting in the budding of the 
particle into the lumen of this compartment (4). Indeed, biochemical and 
immunocytochemical studies have suggested that the S protein initially forms dimers, 
catalyzed by protein disulfide isomerase (PDI) in the ER compartment, before its 
transport in vesicles, as transmembrane dimers, to the ERGIC (24). The absence of 
PDI and the presence of different molecules in the lumen of the ERGIC would thus 
lead to reorganization of the interdimer disulfide bridges, an essential step in the 
assembly of the subviral particles (24). However, the formation of interdimer disulfide 
bridges may not be required for particle formation, because most S proteins in 
particles freshly secreted from transfected cells are dimeric and S mutants with 
multiple cysteine-to-serine substitutions nonetheless form particles (27, 45). 
However, direct interactions within S protein subunits are probably required for the 
formation of subviral envelope particles. Coproduction of the human HBV S protein 
with its counterpart from an animal hepadnavirus showed that the human and duck 
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HBV S proteins did not form mixed subviral particles, despite clear structural and 
sequence similarities, whereas human and woodchuck HBV S, which are more 
closely related, coassembled efficiently (18). It should also be pointed out that the 
current model for subviral HBV particle formation is based principally on studies 
including no ultrastructural analysis of the transfected cells (24). Our EM 
observations clearly show that the HBV subviral particle formed by the S protein 
assembles in the ER compartment. Indeed, this phenomenon clearly occurred at ER-
related membranes, as the membranes had ribosomes on their surface and/or were 
continuous with the outer membrane of the nuclear envelope. The HBV subviral 
particles with a filamentous shape formed by the S protein were initially packed into 
vesicles budding from the ER, and were then delivered by these vesicles to large 
cisternae, in which they were unpacked and relaxed. These large cisternae had 
smooth membranes and probably corresponded to the ERGIC compartment. 
Unfortunately, it was technically difficult to confirm this hypothesis by immunogold 
labeling with an anti-ERGIC antibody. The use of Epon resin and standard EM 
techniques was required to visualize the filaments in this compartment, but the 
results obtained with anti-ERGIC antibody on ultrathin sections of Epon-embedded 
cells were unsatisfactory. The HBV subviral filaments formed by the S protein and 
purified from cell lysates appeared on negative staining to be much longer (up to 1.2 
micrometers) than expected from the size of the intracellular vesicles in which they 
were packed (0.2 to 0.3 micrometers). In addition, these particles were often 
branched. This indicates that they were probably folded in the vesicles during 
intracellular trafficking between the ER and the ERGIC. This folding was properly 
organized, as these packed filaments had a regular, crystal-like structure and were 
presumably bridged in the vesicles. It has been suggested that chaperones, such as 
calnexin (36, 44) or BiP (10), are involved in the assembly and morphogenesis of the 
HBV subviral envelope particles. The ERp57 protein, which is a close homologue of 
PDI, has also been shown to have chaperone activities in conjunction with calnexin 
and calreticulin, forming transient mixed disulfide bridges with cellular proteins 
bearing cysteines (22, 23). These ER-resident proteins may therefore assist with the 
folding and packing of the HBV subviral envelope filaments during their transport in 
ER-derived vesicles. The concentrations of these proteins are lower in the ERGIC, 
which might result in the release of the filaments from these crystal-like structures, as 
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suggested by our EM observations showing the relaxation of filaments in this 
compartment.  
We were unable to identify the morphological events following the release of 
the HBV S subviral filaments in the ERGIC. This is not entirely surprising, as the HBV 
S protein remains in pre-Golgi compartments for almost all of its long lifetime within 
the cell (31). The high-mannose oligosaccharide chains added to the S protein are 
converted to the complex form just before secretion, indicating that this protein is 
rapidly transported to the cell surface through the Golgi apparatus and the final 
constitutive pathway of vesicular transport (31). It has been suggested that the long 
half-time of HBV S protein secretion may be accounted for by the rate-limiting step of 
its assembly into a subviral particle (41). However, we show here that the assembly 
of the HBV S protein into filamentous particles is an early event, followed by the 
transport of these filaments towards a compartment probably corresponding to the 
ERGIC. The rate-limiting step in secretion therefore seems to be the transfer of these 
particles from the ERGIC to the Golgi apparatus. The filamentous shape of these 
particles may limit the size of the particles that can be accommodated within 
transport vesicles. The rate of transport would then be determined by the rate of 
conversion of a filamentous particle to a more spherical particle. Our observations of 
HBV S filaments purification by affinity chromatography and the analysis of these 
filaments by negative staining provide support for this hypothesis, demonstrating that 
these filaments can be spontaneously converted into spherical particles. Subviral 
spherical particles purified from the serum of HBV S-transgenic mice were recently 
reconstructed by cryo-EM, and were found to be very heterogeneous in size (19). 
This may be due to their formation by dissociation from a precursor filamentous 
particle. However, it should be noted that extremely long filaments could be 
transported from the ER to the ERGIC, within small transport vesicles. This may be 
due to the presence of specific chaperones in the ER compartment, making it 
possible to fold and to cross-link these long filaments in transport vesicles. In our 
system, only tiny amounts of HBs Ag were secreted from the transfected cells. This 
low level of secretion may be accounted for by the high toxicity of the SFV 
expression system, making it impossible to culture cells for longer than 24 hours, 
together with the long half-time of HBs Ag secretion. However, HBV subviral particles 
collected from the supernatant of transfected cells were purified by affinity 
chromatography and studied by negative staining. Few particles were recovered from  
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these experiments, but these secreted HBV subviral particles appeared to be 
spherical, suggesting that the conversion of the filaments to spheres is a prerequisite 
for their secretion (data not shown). A construct bearing the HBV S gene under the 
control of the CMV promoter was found to give a ten-fold more efficient HBs Ag 
secretion than the SFV expression vector, but ultrathin sections of the transfected 
cells showed no morphological events typical of subviral envelope particle assembly 
and trafficking. However, the quantification of intracellular HBs Ag by ELISA showed 
similar amount with the two expression systems (data not shown). The visualisation 
of the subviral envelope particle assembly with the SFV RNA vectors may be due to 
a more rapid protein synthesis with this system, leading to a major intracellular 
accumulation of HBs Ag in the early compartments of the secretory pathway. Also, 
our efforts to visualise this phenomenon in hepatoma cells such as the Huh7 cell line 
were unsuccessful, but we have previously observed that the SFV vectors are less 
efficient in these cells (2). 
Many 0.2-0.3 m vesicles packed with HBV S filaments were seen in the 
perinuclear area of the cells, but we observed no extrusion of HBV S filaments from 
the membranes of these vesicles, despite intensive EM analysis of the cells 8, 12 
and 16 hours after transfection. Previous studies have shown that the subviral 
particles contain only 25 % lipid (in terms of weight) (17), so the lipids are unlikely to 
be organized as in conventional membrane bilayer. The absence of a lipid bilayer in 
spherical HBV S particles was recently confirmed by cryo-EM analysis (19). Thus, the 
process resulting in delivery of the HBV S filament to the ER lumen may differ from 
conventional viral budding. Some EM observations such as those presented in Figs. 
3A and 3B suggest that HBV S filaments are assembled de novo in the ER lumen, 
and that a cluster of packaged filaments initiates the budding of a forthcoming 
transport vesicle. Further investigation is required to confirm or reject this hypothesis. 
The production of HBV M and L proteins with an SFV vector had contrasting 
effects. HBV M protein production did not lead to formation of intracellular 
filamentous or spherical subviral envelope particles, although the pSFV1-MHBsadw 
construct also produced the HBV S protein. This lack of particle formation may be 
accounted for by the much lower level of HBV S protein production induced by the 
pSFV1-MHBsadw construct than by pSFV1-SHBsadw. However, HBs Ag levels were 
higher in the supernatant of cells transfected with the pSFV1-MHBsadw construct than 
in the supernatant of cells transfected with the pSFV1-SHBsadw construct. Confocal 
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microscopy also showed the subcellular distribution of HBs Ag in the cytoplasma of 
these cells to be more diffuse. This may reflect a specific role of the M protein in 
enhancing HBV subviral particle trafficking through the secretory pathway. The M 
protein is dispensable for virion or subviral envelope particle formation, but an M 
protein lacking its specific N-linked carbohydrates may inhibit virion (3, 28) or subviral 
envelope particle (42, 44) secretion. The co-production of a fully glycosylated M with 
S may therefore promote trafficking of the HBV subviral envelope particles toward the 
cell surface, as previously suggested (44). Alternatively, we cannot exclude that the 
HBV M protein could have a specific cytotoxic effect leading to HBs Ag release in the 
cell supernatant. This phenomenon, together with lower levels of S production, may 
account for our failure to detect HBV subviral particles in sections of cells transfected 
with pSFV1-MHBsadw. In contrast, the HBV L protein production led to the 
morphogenesis of small branched filaments that seemed to accumulate in the lumen 
of a convoluted, ER-related compartment. Similar ultrastructural observations have 
been reported with Huh7 hepatoma cells producing HBV L protein alone (46), but our 
study allowed to compare the morphogenesis of HBV L filaments directly with that of 
HBV S filaments. Unlike the HBV S filaments, the HBV L filaments were never found 
packed and bridged in small transport vesicles, and were not targeted to a distal 
compartment. However, we cannot exclude the possibility that HBV L filaments are 
transported from the ER to the ERGIC, although if such transport does occur it may 
be less efficient for these filaments than for HBV S filaments. This hypothesis is 
supported by the colocalization of HBV L with ERGIC53 on confocal microscopy, 
which was found to be weaker than that for the HBV S and M proteins. These 
observations may reflect different affinities of these proteins for the cellular 
chaperones, which may subsequently contribute to intracellular retention of the HBV 
L protein. 
In conclusion, our study sheds new light on the mechanisms involved in HBV 
subviral envelope particle morphogenesis and intracellular trafficking through the 
secretory pathway. As the intracellular accumulation of subviral envelope filaments 
may be directly linked to the pathogenesis of HBV (9, 33, 37), improvements in our 
understanding of these mechanisms might facilitate the design of new antiviral 
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FIG. 1. Analysis of HBV envelope protein production in BHK-21 cells transfected with 
pSFV1-SHBsadw, pSFV1-MHBsadw or pSFV1-LHBsadw. Western blots showed that the 
transfection with the pSFV1-SHBsadw construct led to the production of S protein in 
large amounts, with equal proportions of the unglycosylated (p24) and glycosylated 
(gp27) forms. Transfection with pSFV1-MHBsadw led to the production within cells of 
the two main forms of the glycosylated M protein (ggp36 and gp33) but only trace 
amounts of the unglycosylated form (p30), with small amounts of the two forms of the 
HBV S envelope protein, p24 and gp27. Transfection with pSFV1-LHBsadw led to the 
production of  the L protein in its unglycosylated (p39) and glycosylated (gp42) forms, 
and to the production of smaller amount of the two glycosylated forms of M. ELISA 
showed that HBsAg levels were twice as high in the supernatant of cells transfected 
with pSFV1-MHBsadw than in the supernatant of cells transfected with pSFV1-
SHBsadw, and that no HBs Ag was present in the supernatant of cells transfectd with 
the pSFV1-LHBsadw and -Gal constructs. Molecular weight markers (M) are 






FIG. 2. Subcellular localization, by confocal microscopy, of the HBV envelope 
proteins in BHK-21 cells transfected with pSFV1-SHBsadw, pSFV1-MHBsadw or 
pSFV1-LHBsadw. All three proteins colocalized at least partly with calreticulin, a 
specific ER marker, and with ERGIC53, a specific ERGIC marker, in the perinuclear 
area. The HBV M protein had a more diffuse subcellular distribution than the S and L 
proteins. The HBV L protein was found mostly colocalized with calreticulin and, to a 
lesser extend, with ERGIC53. Cells transfected with a recombinant SFV RNA 




FIG. 3. Early ultrastructural changes in BHK-21 cells producing the HBV S protein. 
Numerous vesicles 0.2 to 0.3 m in diameter (short arrows), packed with 22 nm large 
filaments, were observed in the perinuclear area. These vesicles originated from the 
ER, as they were frequently observed budding from the nuclear envelope (A and its 
inset) or from membranes carrying ribosomes (indicated by the long arrows in B). 
The filaments packed in these vesicles appeared in lengthwise (open arrows) or 
crosswise (closed arrows) sections in crystal-like structures (see a high magnification 
of these packed filaments in the inset in C). The specificity of these filaments was 
studied by immuno-EM using the rabbit anti-HBs PAb. Modifications to the fixation 
and embedding procedures required for this specific immunostaining method, 
resulted in cell structures and filaments being less well preserved than in cells 
embedded in Epon resin and subjected to standard EM procedures, but intense gold 
labeling restricted to these vesicles and predominantly found in the perinuclear area 
was observed (inset in D). No specific ultrastructural changes were observed in cells 
producing -Gal (not shown on figures). Bars, 0.2 micrometers; N, nucleus; ER, 




FIG. 4. Late ultrastructural changes in BHK-21 cells producing the HBV S protein. 
Very large cisternae with smooth membranes, 1 to 2 micrometers in diameter, were 
found to contain interlaced relaxed 22 nm diameter filaments (A). The ends of these 
filaments appeared electron-dense (see a high magnification of these filaments in the 
inset in A). The fusion of vesicles transporting packed filaments with the membranes 
of cisternae was frequently observed (large arrows in B, C and D), suggesting that 
the lumina of these cisternae contained material provided by the vesicles with the 
packed filaments. Filaments in the lumen were sometimes relaxed to one end, with 
the other end remaining associated with a cristal-like structure and other filaments 
(small arrows in A, C and D). These ultrastructural changes were never observed in 






FIG. 5. Negative staining of the intracellular subviral envelope filaments purified from 
cells producing the HBV S protein. A first round of purification on a sucrose gradient 
resulted in long filaments with a diameter of 22 nm and a regular crenellated 
appearance (A and B), often branched (arrows in B). These filaments displayed 
immunoagglutination with a rabbit anti-HBs PAb and were immuno-gold labeled 
(inset in A). A second round of purification by affinity chromatography resulted in 






FIG. 6. EM analysis of BHK-21 cells transfected with pSFV1-MHBsadw and pSFV1-
LHBsadw, and of HBV envelope particles recovered from these cells. No 
ultrastructural changes were detected in cells transfected with pSFV1-MHBsadw (A), 
or the -Gal construct (not shown on figures). Cells transfected with pSFV1-LHBsadw 
showed dilated convoluted compartments containing large, branched and relaxed 
filamentous particles (B and C). This compartment was ER-related, as its membranes 
were rough and sometimes continuous with the external membrane of the nuclear 
envelope (white arrows). Negative staining of the filaments recovered from these 
cells led to the observation of small branched filaments with a diameter of 30 nm (D). 
Bars in A, B and C, 0.2 micrometers; Bar in D, 100 nm; N, nucleus; ER, endoplasmic 
reticulum; Cy, cytoplasma. 
